This two-way crossover study investigated possible differences between the proton pump inhibitors, omeprazole and rabeprazole, in their effect on gastric acid secretion in Japanese subjects with differing cytochrome P450, family 2, subfamily C, polypeptide 19 (CYP2C19) genotypes. A total of 23 Helicobacter pylorinegative healthy volunteers received omeprazole 20 mg/day and rabeprazole 10 mg/day. Each drug treatment was given for a continuous 7-day period allocated in random order, with an interval of at least 1 week between drug treatment periods to allow for wash-out. Intragastric pH was measured on days 1 and 7. Overall median intragastric pH levels at 7 and 8 h after the first administration were significantly higher with omeprazole. There was no significant difference in intragastric pH in homozygous extensive metabolizers, whereas intragastric pH was significantly higher with omeprazole in combined data from heterozygous extensive metabolizers and poor metabolizers at 6, 7 and 8 h after the first drug administration. There were no significant differences in intragastric pH between omeprazole and rabeprazole irrespective of genotype on day 7 of administration. In conclusion, on day 1 the time to onset of the antisecretory action of 20 mg/day omeprazole was more rapid than that of 10 mg/day rabeprazole in Japanese individuals who have a higher incidence of the CYP2C19 poor metabolizer genotype, however by day 7 no difference in antisecretory effect was found, regardless of genotype.
Introduction
Studies have shown that the number of patients with gastro-oesophageal reflux disease (GORD) is increasing in Japan. 1 -3 K Furuta, K Adachi, S Ohara et al.
Proton pump inhibitors and CYP2C19 genotype
The presence of GORD-related symptoms, such as heartburn and regurgitation, has a major impact on patients' quality of life. 4 -7 The primary method for controlling symptoms is suppression of gastric acid secretion, with proton pump inhibitors (PPIs) being widely used as therapeutic agents. PPIs, such as omeprazole, lansoprazole and rabeprazole, inhibit gastric acid secretion by selectively and non-competitively inactivating H + ,K + -ATPase in parietal cells 8, 9 and are considered to be the most effective medical treatment for GORD. 10 -12 Omeprazole and lansoprazole are primarily metabolized in the liver, and polymorphic cytochrome P450, family 2, subfamily C, polypeptide 19 (CYP2C19) is known to be involved in their metabolism. 13 -16 Three CYP2C19 genotypes have been identifiedhomozygous extensive metabolizer (homEM), heterozygous extensive metabolizer (hetEM) and poor metabolizer (PM). 14 -16 Several studies have reported that the metabolism of omeprazole and lansoprazole is influenced by the CYP2C19 genotype. 13 -16 Rabeprazole is degraded in a non-enzymatic manner and is only partially metabolized by CYP2C19 and cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4). 17 -19 Thus, its acid-inhibitory effects are assumed to be less influenced by CYP2C19 genotype status compared with other PPIs. Furthermore, previous studies have shown that rabeprazole has a more rapid onset of acid-suppressing action than omeprazole and lansoprazole. 20 -23 In the present study, intragastric acidity was measured following administration of standard doses of the two different PPIs, omeprazole and rabeprazole, to determine any differences in the time to onset of antisecretory action. The effect of CYP2C19 genotype on the inhibitory effect of acid secretion was also investigated.
Subjects and methods

SUBJECTS
Healthy,
Helicobacter pylori-negative Japanese volunteers were recruited sequentially to the study from medical students at Shimane University Faculty of Medicine between January and August 2009. Exclusion criteria included upper gastrointestinal symptoms, a history of upper gastrointestinal surgery and receipt of medications known to influence gastric acid secretion.
Written informed consent was obtained from all study participants. The study was approved by the Ethics Committee of Shimane University, Shimane, Japan, and was carried out in accordance with the Declaration of Helsinki.
H. PYLORI STATUS
Urine samples were obtained from subjects. The absence of H. pylori infection was confirmed by measuring H. pylori antibody levels in urine using the commercially available Rapirun ® kit (Otsuka Pharmaceutical Co., Tokushima, Japan), which utilizes immunochromatography, according to the manufacturer's instructions.
CYP2C19 GENOTYPING
Blood was obtained from subjects, and DNA was extracted from leucocytes using the commercially available Genomix kit (Talent, Trieste, Italy) according to the manufacturer's instructions. Genotyping procedures for identifying the CYP2C19 wildtype gene and two mutated alleles on exons 5 and 4 were performed by a polymerase chain reaction-restriction fragment length polymorphism method using allele-specific primers as described by De Morais et al., 24 with minor modifications as reported by Kubota et al. 25 
PPI PROTOCOL
Subjects were given 20 mg/day omeprazole (Omepral ® ; AstraZeneca, Osaka, Japan) and 10 mg/day rabeprazole (Pariet ® ; Eisai Pharmaceutical Co., Tokyo, Japan), each for 7 days; these are standard doses for the treatment of gastric/duodenal ulcers and reflux oesophagitis in Japan. Compliance was assessed by checking the presence of any remaining tablets on day 7. The drugs were given in random order, with an interval of at least 1 week to allow for wash-out of the previously administered PPI.
MEASUREMENT OF INTRAGASTRIC PH
All subjects underwent ambulatory 24-h intragastric pH monitoring (from 18.00 h on day 1 to 18.00 the following day) on days 1 and 7 following administration of omeprazole or rabeprazole after the evening meal (dinner). An antimony pH catheter (Zinetics Medical, Salt Lake City, UT, USA) was positioned on the greater curvature of the middle body of the stomach under fluoroscopic guidance. Calibration was performed prior to each recording according to the manufacturer's recommendations.
The pH values were recorded on a Digitrapper™ Mark III (Synectics Medical, Stockholm, Sweden) and the values obtained were transferred to the commercially available Esophagogram software program (Gastrosoft, Stockholm, Sweden).
Ambulatory pH monitoring was undertaken with the subjects on a standard diet, which provided a daily total of 983 kcal consisting of 20.9 g protein, 15.4 g lipids and 190.1 g carbohydrates. The individual calorie allowances for breakfast, lunch and dinner were 235, 336 and 412 kcal, respectively. Meals were provided at 08.00 h (breakfast), 12.00 h (lunch) and 18.00 h (dinner), with no additional food being permitted and 100 ml of tap water allowed only when thirsty. Subjects were instructed to remain upright until 22.30 h and then to remain recumbent all night until 06.30 h.
STATISTICAL ANALYSIS
Statistical analysis was performed using a Wilcoxon signed rank test for paired data and unpaired t-test for unpaired data. All calculations were done using the StatView ® software package, version 5.0 (Abacus Concepts, Berkeley, CA, USA) for Macintosh. A P-value < 0.05 was considered to be statistically significant.
Results
A total of 23 healthy volunteers (17 men, six women) with a mean age of 23.2 years (range 19 -30 years) were included in the study. Subjects were divided into three groups on the basis of their CYP2C19 genotype. Ten subjects (43.5%) were homozygous for the wild-type allele on both exon 5 and exon 4 and were classified as homEM, nine (39.1%) were heterozygous for the wild-type allele on either exon 5 or exon 4 and were classified as hetEM, and four subjects (17.4%) were heterozygous on both exon 5 and exon 4 or had homozygous mutated alleles on these exons and were classified as PM (Table 1) .
The median intragastric pH for the 23 subjects over 24 h following the first dose of omeprazole and rabeprazole is shown in Fig.  1 . The pH values initially fell following food intake but, from 4 h after dosing, they began to rise for the next 11 h for both omeprazole and rabeprazole, and the pHs at 7 and 8 h were significantly higher with omeprazole compared with rabeprazole (P < 0.05). The intragastric pH over 24 h following the first dose of omeprazole and rabeprazole in the three different genotype groups is shown in Fig. 2 . There were no statistically significant differences in the intragastric pH values in the K Furuta, K Adachi, S Ohara et al. Proton pump inhibitors and CYP2C19 genotype homEM and hetEM groups between omeprazole and rabeprazole ( Fig. 2A, 2B ). In the PM group, the intragastric pH during the first 12 h tended to be higher with omeprazole ( Fig. 2C ). When the results for the hetEM and PM groups were combined, the intragastric pHs at 6, 7 and 8 h after administration were significantly higher with omeprazole than with rabeprazole (P < 0.05; Fig. 3 ).
Following omeprazole administration, there were marked differences in acid-suppressing effects during day 1 among the different CYP2C19 genotypes. In the PM group, the intragastric pH after the first omeprazole administration was significantly higher at 1, 2, 9 and 12 -21 h (P < 0.05 or P < 0.01) and became elevated sooner than in the homEM group. In contrast, this was not observed after rabeprazole administration, even in subjects with the PM genotype.
The intragastric pH in 22 subjects over 24 h on day 7 of omeprazole and rabeprazole Fig. 4 ; data were not available from the remaining subject, a homEM, due to technical problems. There were no statistically significant differences in intragastric pH over 24 h on day 7 of omeprazole and rabeprazole according to genotype (Fig. 5 ).
Discussion
The PPIs have a potent inhibitory effect on gastric acid secretion and are widely used for the treatment of acid-related diseases. 26 In the treatment of GORD, rapid acid suppression is important for quick control of unpleasant reflux symptoms, 27,28 though 29 For example, omeprazole has been reported to have a weak first-day inhibitory effect compared with rabeprazole. 20 -22 The different levels of potency and speed of PPI-induced inhibition are caused not only by differences in the ability of the drug to bind to proton pumps, but also activation and catabolism of the PPI.
The PPIs are primarily metabolized by cytochrome P450 in the liver. 13 -16 Although CYP3A4 is partially involved in PPI catabolism, the major pathway of PPI inactivation is regulated by CYP2C19. There are three CYP2C19 genotypes -homEM, hetEM and PM -that differentially affect the metabolism of omeprazole. Plasma PPI concentration and intragastric pH in homEM subjects have been reported as significantly lower than in PM subjects. 30 In contrast, rabeprazole has been reported to be only partially metabolized by these enzymes and to show a more consistent acid-suppressing effect than other PPIs that are mainly metabolized by CYP2C19. 30 The proportions of PM, hetEM and homEM individuals in a Caucasian population have been reported to be 3%, 30% and 67%, respectively, 31 while among the Japanese population approximately 20% of individuals are PMs. 32, 33 In previous reports, the majority of data concerning the acid-suppressing effect of omeprazole were collected in studies of Caucasian populations, which have a smaller percentage of individuals with the PM genotype. 34 Thus, the acid-suppressing effects of omeprazole are considered to be stronger in the Japanese population, as it has a larger percentage of individuals with the PM genotype; higher plasma levels of omeprazole should be achievable in this genotype because of the slower degradation of omeprazole. The proportion of individuals with the PM, hetEM and homEM genotypes in the present study were 17.4%, 39.1% and 43.5%, respectively, which was similar to previously reported percentages in the Japanese population. 25, 32, 33, 35 The lower percentage of homEM genotypes, who degrade PPIs most rapidly, was in strong contrast to the much higher percentage (approximately 70%) observed in Caucasians. 31, 36 Following separate administrations of omeprazole (20 mg/day) and rabeprazole (10 mg/day) in the present study, the median intragastric pH after the first administration initially fell following food intake but, from 4 h after dosing, began to rise for the next 11 h irrespective of the administered PPI. During the first day following omeprazole administration, the different CYP2C19 genotypes showed marked differences in acidsuppressing effects. Intragastric pH in the PM group was significantly higher and became elevated more quickly than in the homEM group. In contrast, this was not observed after rabeprazole administration. Thus, augmentation of the acid-suppressing effect in PM subjects, which comprise approximately 20% of the Japanese population, was observed with omeprazole, but not with rabeprazole, indicating that omeprazole is a stronger inhibitor of gastric secretion on the first administration day in PM individuals. In contrast, the acid-suppressing effects of omeprazole and rabeprazole were similar in the homEM group.
Rabeprazole is known to act more rapidly than other PPIs. For example, Pantoflickova et al. 29 investigated intragastric pH after single doses of four different PPIs, including 20 mg omeprazole and 20 mg rabeprazole, and reported that the acid-suppressing effect of rabeprazole was stronger and appeared more quickly than that of omeprazole. The dose of rabeprazole used was twice that typically used Proton pump inhibitors and CYP2C19 genotype in Japan (10 mg) and the drug was given to volunteers living in the UK; CYP2C19 genotype information was not reported. Inamori et al. 37 compared the acid-suppressing effects of single administrations of omeprazole and rabeprazole in Japanese subjects, although they also used 20 mg doses of each. These authors found no difference overall between the drugs with regard to their acid-suppressing effect on the first administration day, but rabeprazole was found to be more effective than omeprazole in CYP2C19 extensive metabolizers. Saitoh et al. 38 also compared omeprazole and rabeprazole in CYP2C19 extensive metabolizers and found that the acid-suppressing effect of omeprazole at 20 mg was weaker than that of rabeprazole at 10 mg, although they did not present any data relating to PM genotypes.
Omeprazole, at a dose of 20 mg/day, had stronger and more rapid effects in terms of acid-suppression than rabeprazole at 10 mg/day in the PM group in the present study in Japanese subjects. In addition, on day 1 of administration without stratifying for CYP2C19 genotypes, omeprazole at 20 mg was stronger than rabeprazole at 10 mg at 7 and 8 h after administration, whereas the two drugs were equally effective at the other time points. On day 7 of administration, the acid-suppressing effects of both drugs were equivalent. Overall, these results suggest that 20 mg/day omeprazole and 10 mg/day rabeprazole are equally effective for the treatment of acid-related disease in Japan, which has a larger percentage of PM genotype individuals compared with Caucasian populations.
The limitations of the present study include its open design and the lack of intragastric pH data without PPI administration. Although the volunteers knew which PPI they were taking, pH monitoring and measurement of intragastric pH were considered to be scarcely influenced if the PPI protocol was adhered to. Compliance to the protocol was found to be good and it was concluded that any possible bias caused by the open design of the study was not large. A further limitation was that intragastric pH was not measured prior to PPI administration, making it difficult to detect the acid-suppressing action of a PPI if the effect was marginal. All of the volunteers were, however, young and negative for H. pylori infection, and were considered to have relatively high levels of gastric acidity; therefore, elevation of intragastric pH above 2.0 could be considered to be caused by the administered PPI.
In conclusion, the present study showed that the time to onset of antisecretory action for 20 mg omeprazole is faster than that of 10 mg rabeprazole in Japanese individuals who have a higher incidence of the CYP2C19 PM genotype. In contrast, by day 7 of administration, no difference in antisecretory effect was found between omeprazole and rabeprazole in any of the subjects, regardless of genotype.
